|
Art is Chairman & Chief Executive Officer for Micell Technologies. In addition, he is a board member and advisor for privately-held biomedical companies, an advisory board member for RA Capital Group and the Chairman of the San Diego-Life Science Accelerator Exploratory Committee. Prior to being named to his current role at Micell Technologies, Art was the interim CEO. In addition and as President of Healthcare Strategies LLC, he has served as Chairman of the Advisory Board for RA Capital Group, an advisor to venture capital firms as well as biotech and medical device companies. He was also an early principal and the Chairman & CEO of Advanced Tissue Sciences, Inc. (ATS), a public biotechnology firm focused on the field of tissue engineering. Prior to joining ATS, Art was associated with Eli Lilly & Company for more than twenty years. He served as President and General Manager of Eli Lilly Canada, Inc. and was President & CEO of IVAC Corp. (now ALARIS/Cardinal Health), a medical device company previously owned by Eli Lilly. Art also held various marketing and sales management positions within the Pharmaceutical Division of Lilly as well as within the medical device subsidiary, IVAC. He holds a B.S. in Pharmacy and an Honorary Doctor of Science from St. John’s University. Art’s previous board appointments include Project HOPE, an international health and education foundation; Scripps Institute of Medicine and Science; The Scripps Research Institute; Scripps Memorial Hospital Foundation (where he served as President); La Jolla Cancer Foundation (Burnham Institute); Board of Overseers for the University of California, San Diego; Governor’s Council on Biotechnology (California); San Diego Economic Development Corporation; City National Bank (San Diego Advisory Board); founding board member of BIOCOM/ San Diego and Chairman of BIOCOM’s Capital Development Committee; privately-held and publicly-traded biomedical companies. | 